Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Pfizer's lyme vaccine moves to final testing phase

NCT ID NCT07226882

First seen Nov 12, 2025 · Last updated May 23, 2026 · Updated 23 times

Summary

This study tests a new Lyme disease vaccine (VLA15) in healthy adults aged 18 to 44. Participants receive five shots over two years, with some getting the vaccine at different times and one shot being a placebo (saltwater). The goal is to see if the vaccine is safe and triggers a strong immune response against Lyme disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYME DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • IMA Clinical Research Warren

    Warren Township, New Jersey, 07059, United States

  • Northeast Clinical Trials Group

    Scranton, Pennsylvania, 18510, United States

  • Preferred Primary Care Physicians

    Uniontown, Pennsylvania, 15401, United States

  • Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)

    Pittsburgh, Pennsylvania, 15236, United States

  • Smith Allergy & Asthma Specialists

    Horseheads, New York, 14845, United States

  • Smith Allergy and Asthma Specialists

    Cortland, New York, 13045, United States

Conditions

Explore the condition pages connected to this study.